Sign In
Buy NVS
$153.38
+4.45 (+2.99%)
At Close: Jun 23, 2026
Peanut allergy is a growing health concern, especially in children, with rising incidence and increased public awareness of its severity and risks. This
Novartis to Launch Direct-to-Patient Platform for Cosentyx in U.S.
08:53am, Monday, 29'th Sep 2025
The company is the latest pharma giant to move on price-cutting ahead of the Trump administration's deadline.
Novartis to Launch Direct-to-Patient Platform for Cosentyx® (secukinumab) in the US
08:15am, Monday, 29'th Sep 2025
Basel, September 29, 2025 – Today, Novartis announced plans to launch a direct-to-patient (DTP) platform in the US which will come into effect on November 1, 2025, offering cash-paying patients pres
Novartis announces commencement of tender offer to acquire Tourmaline Bio
07:44am, Monday, 29'th Sep 2025
Basel, September 29, 2025 - Novartis today announced that Torino Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis (“Purchaser”), has commenced a tender
Novartis to showcase transformative data in advanced prostate and early breast cancer at ESMO 2025
01:15am, Friday, 26'th Sep 2025
Basel, September 26, 2025 – Novartis will present new data from 34 abstracts across its oncology portfolio at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin (October 17-21,
New Novartis data further support benefits of Kesimpta® in relapsing MS following switch from oral disease modifying therapies
02:30am, Wednesday, 24'th Sep 2025
Basel, September 24, 2025 – Novartis today announced new data from two Kesimpta® (ofatumumab) studies in relapsing multiple sclerosis (RMS) that will be presented at the European Committee for Trea
Novartis ramps up US stockpiles to shield against potential tariffs
10:41am, Saturday, 20'th Sep 2025
Novartis AG (NOVN.S) has significantly increased its stockpiles of pharmaceuticals in the United States and is positioning itself to withstand potential tariffs, Chief Executive Officer Vas Narasimhan
Novartis has stockpiles to withstand potential Trump tariffs, CEO says
06:00am, Saturday, 20'th Sep 2025
Novartis has increased its stockpiles of pharmaceuticals in the United States and is well prepared should its products be hit by President Donald Trump's tariffs, its chief executive said in an interv
Why Novartis (NVS) is a Top Value Stock for the Long-Term
10:41am, Thursday, 18'th Sep 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Is Novartis (NVS) Stock Outpacing Its Medical Peers This Year?
10:41am, Wednesday, 17'th Sep 2025
Here is how Novartis (NVS) and Arbutus Biopharma (ABUS) have performed compared to their sector so far this year.
Monte Rosa's Stock Gains on Signing $5.7B Licensing Deal With Novartis
10:51am, Tuesday, 16'th Sep 2025
GLUE surges 44% after sealing a $5.7B licensing deal with NVS to advance molecular glue degraders for immune diseases.
Monte Rosa, Novartis Use AI-Powered Engine To Advance Immune Disease Treatments
11:29am, Monday, 15'th Sep 2025
Monte Rosa Therapeutics Inc. GLUE stock is surging on Monday, with a session volume of 11.67 million compared to the average volume of 408.08 thousand as per data from Benzinga Pro.
Monte Rosa Therapeutics Announces Collaboration with Novartis for Degraders to Treat Immune-mediated Diseases
07:00am, Monday, 15'th Sep 2025
Novartis receives an exclusive license to an undisclosed discovery target Novartis also receives options to license two programs from Monte Rosa's growing preclinical immunology portfolio Monte Rosa
Novartis Catches a ‘Sell.' Goldman Sachs Says the Stock Is Overvalued.
12:11pm, Friday, 12'th Sep 2025
Only 20% of analysts tracked by FactSet rate the stock at Buy.
NVS to Acquire TRML, Add Phase III Cardiovascular Drug to Pipeline
12:11pm, Wednesday, 10'th Sep 2025
Novartis is set to acquire Tourmaline Bio for $1.4B, adding late-stage anti-IL-6 candidate pacibekitug to its cardiovascular pipeline.
